Simvastatin-ezetimibe combination therapy is associated with a lower rate of major adverse cardiac events in type 2 diabetics than high potency statins alone: A population-based dynamic cohort study

International Journal of Cardiology

Volumn 190, Issue 1, 2015, Pages 20-25

  Chang, Shang Hung ^a   Wu, Lung Sheng ^a   Lee, Cheng Hung ^a   Kuo, Chi Tai ^a   Liu, Jia Rou ^b   Wen, Ming Shien ^a   Chen, Wei Jan ^a   See, Lai Chu ^a,b   Yeh, Yung Hsin ^a  

^a CHANG GUNG UNIVERSITY   (Taiwan)

^b CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

Major adverse cardiac events; Simvastatin ezetimibe; Statins; Type 2 diabetes

Indexed keywords

ATORVASTATIN; EZETIMIBE PLUS SIMVASTATIN; ROSUVASTATIN; DRUG COMBINATION; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT;

ADULT; AGE; AGED; ARTICLE; BLOOD CLOT LYSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; CORONARY ARTERY BYPASS SURGERY; DRUG POTENCY; FEMALE; HEART ARRHYTHMIA; HEART DISEASE; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERTENSION; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PERCUTANEOUS CORONARY INTERVENTION; POPULATION RESEARCH; PRIORITY JOURNAL; SEX DIFFERENCE; SHOCK; TAIWAN; DIABETES MELLITUS, TYPE 2; DRUG COMBINATION; HEALTH SURVEY; LONGITUDINAL STUDY; TREATMENT OUTCOME;

ADULT; AGED; ANTICHOLESTEREMIC AGENTS; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; DRUG COMBINATIONS; EZETIMIBE, SIMVASTATIN DRUG COMBINATION; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; POPULATION SURVEILLANCE; TAIWAN; TREATMENT OUTCOME;

EID: 84929329231     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2015.04.121     Document Type: Article

References (23)

1. G.H. Tomkin, Targets for intervention in dyslipidemia in diabetes, Diabetes Care 31 (2008) S241-S248.
2. N.J. Stone, J. Robinson, A.H. Lichtenstein, C.N.B. Merz, C.B. Blum, R.H. Eckel, et al., 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, Circulation 129 (25) (2014) S1-S45.
3. S. Rabar, M. Harker, N. O'Flynn, A.S. Wierzbicki, G.D. Group, Lipid modification and cardiovascular risk assessment for the primary and secondary prevention of cardiovascular disease: summary of updated NICE guidance, BMJ 349 (2014) g4356.
4. R.W. Nesto, P.P. Singh, Diabetes and residual risk of coronary heart disease, Nat. Clin. Pract. Endocrinol. Metab. 3 (2007) 71.
5. M.H. Davidson, T. McGarry, R. Bettis, L. Melani, L.J. Lipka, A.P. LeBeaut, et al., Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia, J. Am. Coll. Cardiol. 40 (2002) 2125-2134.
6. A.C. Goldberg, A. Sapre, J. Liu, R. Capece, Y.B. Mitchel, E.S. Group, Efficacy and safety of ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia: a randomized, double-blind, placebo-controlled trial, Mayo Clin. Proc. 79 (2004) 620-629.
7. J.D. Goldman-Levine, L.G. Bohlman, Ezetimibe/simvastatin (vytorin) for hypercholesterolemia, Am. Fam. Physician 72 (2005) 2081-2082.
8. M. Sarigianni, N. Katsiki, D.P. Mikhailidis, Ezetimibe indiabetes: more than cholesterol lowering? Curr. Med. Res. Opin. 26 (2010) 2517-2520.
9. A.E.P. Pesaro, C.V. Serrano, J.L. Fernandes, A.B. Cavalcanti, A.H. Campos, H.S. Martins, et al., Pleiotropic effects of ezetimibe/simvastatin vs. high dose simvastatin, Int. J. Clin. Pract. 158 (2012) 400-404.
10. E. Moutzouri, E.N. Liberopoulos, C.C. Tellis, H.J. Milionis, A.D. Tselepis, M.S. Elisaf, Comparison of the effect of simvastatin versus simvastatin/ezetimibe versus rosuvastatin on markers of inflammation and oxidative stress in subjects with hypercholesterolemia, Atherosclerosis 231 (2013) 8-14.
11. R. Krysiak, W. Zmuda, B. Okopien, The effect of simvastatin-ezetimibe combination therapy on adipose tissue hormones and systemic inflammation in patients with isolated hypercholesterolemia, Cardiovasc. Ther. 32 (2014) 40-46.
12. A.B. Rossebø, T.R. Pedersen, K. Boman, P. Brudi, J.B. Chambers, K. Egstrup, et al., Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis, N. Engl. J. Med. 359 (2008) 1343-1356.
13. C. Baigent, M.J. Landray, C. Reith, J. Emberson, D.C. Wheeler, C. Tomson, et al., The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial, Lancet 377 (2011) 2181-2192.
14. C.P. Cannon, IMPROVE-IT Trial: a comparison of ezetimibe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes after acute coronary syndromes. 2014 Late-Breaking Clinical Trial Abstracts, Circulation 130 (2014) 2105-2126.
15. S.-W. Chen, Y.-T. Tsan, J.-D. Chen, H.-I. Hsieh, C.-H. Lee, H.-H. Lin, et al., Use of thiazolidinediones and the risk of colorectal cancer in patients with diabetes: a nationwide, population-based, case-control study, Diabetes Care 36 (2013) 369-375.
16. T.-F. Chao, H.-B. Leu, C.-C. Huang, J.-W. Chen, W.-L. Chan, S.-J. Lin, et al., Thiazolidinediones can prevent new onset atrial fibrillation in patients with non-insulin dependent diabetes, Int. J. Cardiol. 156 (2012) 199-202.
17. H.E. Bays, M. Averna, C. Majul, D. Muller-Wieland, A. De Pellegrin, H. Giezek, et al., Efficacy and safety of ezetimibe added to atorvastatin versus atorvastatin uptitration or switching to rosuvastatin in patients with primary hypercholesterolemia, Am. J. Cardiol. 112 (2013) 1885-1895.
18. O.C. Mangili, A.C. Moron Gagliardi, L.C. Mangili, C.H. Mesquita, L.A. Machado Cesar, A. Tanaka, et al., Favorable effects of ezetimibe alone or in association with simvastatin on the removal from plasma of chylomicrons in coronary heart disease subjects, Atherosclerosis 233 (2014) 319-325.
19. C.M. Ballantyne, R.C. Hoogeveen, J.L. Raya, V.A. Cain, M.K. Palmer, B.W. Karlson, et al., Efficacy, safety and effect on biomarkers related to cholesterol and lipoprotein metabolism of rosuvastatin 10 or 20 mg plus ezetimibe 10 mg vs. simvastatin 40 or 80 mg plus ezetimibe 10 mg in high-risk patients: results of the GRAVITY randomized study, Atherosclerosis 232 (2014) 86-93.
20. M. Farnier, K. Retterstøl, A. Steinmetz, A. Császár, Comparative efficacy and safety of fenofibrate/pravastatin plus ezetimibe triple therapy and simvastatin/ezetimibe dual therapy in type 2 diabetic patients with mixed hyperlipidaemia and cardiovascular disease, Diabetes Vasc. Dis. Res. 9 (2012) 205-215.
21. S.N. Rajpathak, D.J. Kumbhani, J. Crandall, N. Barzilai, M. Alderman, P.M. Ridker, Statin therapy and risk of developing type 2 diabetes: a meta-analysis, Diabetes Care 32 (2009) 1924-1929.
22. N. Sattar, D. Preiss, H.M. Murray, P. Welsh, B.M. Buckley, A.J.M. de Craen, et al., Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials, Lancet 375 (2010) 735-742.
23. C.R. Dormuth, K.B. Filion, J.M. Paterson, M.T. James, G.F. Teare, C.B. Raymond, et al., Higher potency statins and the risk of new diabetes: multicentre, observational study of administrative databases, BMJ 348 (2014) g3244.